TruGenomix Wins Southeast Life Sciences SE Color Pitch

The first SE Color Pitch event, hosted by Southeast Life Sciences, was held on June 24, 2021, featuring top minority-led, early-stage life science companies from the southeast United States.

The winner of the SE Color Pitch event, TruGenomix, which will receive the $10,000 prize, sponsored by Moderna. Presenting for TruGenomix was Charles Cathlin. CEO & Founder.

TruGenomix is a precision behavioral health company focused on advancing the diagnosis and treatment of mental health conditions such as post-traumatic stress disorder (PTSD). Our behavioral health platform incorporates our core products, TruGen-1and TruBase. TruGen-1 is a 1000 gene neuropsychiatric panel, designed in collaboration with Illumina, that includes our patented markers for PTSD predisposition. TruBase is our custom-built machine learning and bioinformatics engine, which is designed to support behavioral health research, clinical decision-making, and biomarker discovery.

See the presentation HERE.

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate, …

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual …

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by …

News